RT Journal Article
T1 Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.
A1 López-Cortés, Luis F
A1 Viciana, Pompeyo
A1 Girón-González, José A
A1 Romero-Palacios, Alberto
A1 Márquez-Solero, Manuel
A1 Martinez-Perez, Maria A
A1 López-Ruz, Miguel A
A1 Torre-Lima, Javier de la
A1 Téllez-Pérez, Francisco
A1 Delgado-Fernández, Marcial
A1 Garcia-Lázaro, Milagros
A1 Lozano, Fernando
A1 Mohamed-Balghata, Mohamed O
K1 Etravirina
K1 Piridazinas
K1 Inhibidores de Proteasas
K1 Estudios Multicéntricos como Asunto
K1 Seropositividad para VIH
K1 Fármacos Anti-VIH
K1 Humanos
K1 Inhibidores de la Proteasa VIH
K1 Inhibidores de Transcriptasa Inversa
AB Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.TRIAL REGISTRATIONClinicalTrials.gov NCT01437241.
PB Public Library of Science
YR 2014
FD 2014-05-16
LK http://hdl.handle.net/10668/1629
UL http://hdl.handle.net/10668/1629
LA en
NO López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, et al. Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE. 2014; 9(5):e97262
NO Journal Article; ClinicalTrials.gov NCT01437241.
DS RISalud
RD Apr 7, 2025